Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

SELL
$21.53 - $26.8 $495,190 - $616,400
-23,000 Reduced 13.14%
152,000 $3.52 Million
Q4 2022

Feb 13, 2023

BUY
$18.63 - $27.35 $3.26 Million - $4.79 Million
175,000 New
175,000 $4.59 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Integral Health Asset Management, LLC Portfolio

Follow Integral Health Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Integral Health Asset Management, LLC with notifications on news.